Valuation: Celsion Corporation

Market Cap 6.77M 5.86M 5.49M 5.01M 9.42M 645M 9.58M 64.36M 25.22M 323M 25.4M 24.85M 1.08B P/E 2026 *
-0.56x
P/E 2027 * -0.71x
Enterprise Value 6.77M 5.86M 5.49M 5.01M 9.42M 645M 9.58M 64.36M 25.22M 323M 25.4M 24.85M 1.08B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
93.55%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 2024-05-12
Director of Finance/CFO 53 2026-06-30
Chief Tech/Sci/R&D Officer 73 2025-02-17
Director TitleAgeSince
Chairman 75 2014-10-06
Director/Board Member 75 2011-07-07
Director/Board Member 76 2015-12-14
Change 5-day change 1-year change 3-year change Capi.($)
-0.70%+13.34%+75.61%+103.83% 70.51B
-2.35%+2.88%+35.39%+64.72% 54.05B
-1.62%+34.25%+17.43%+491.04% 28.95B
-1.17%+11.87%+53.72%+6.79% 24.05B
0.00%+1.59%-15.06%-13.21% 23.31B
+0.05%+6.12%+46.81%-21.81% 18.37B
+9.77%+20.16%+260.17%+472.38% 18.67B
-0.38%+7.06%+30.45%+621.23% 16.1B
-3.08%-8.34%+37.21%+138.52% 12.72B
Average +0.06%+395.57%+60.19%+207.06% 29.64B
Weighted average by Cap. -0.43%+350.15%+57.62%+168.98%

Financials

2026 *2027 *
Net sales - -
Net income -14.93M -12.94M -12.12M -11.06M -20.8M -1.42B -21.15M -142M -55.66M -713M -56.07M -54.85M -2.38B -24.88M -21.56M -20.18M -18.42M -34.65M -2.37B -35.24M -237M -92.72M -1.19B -93.41M -91.37M -3.96B
Net Debt - -
Logo Celsion Corporation
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-